PROTAC Shrinks Mutated Prostate Tumors
Unknown authors
Abstract
The most clinically advanced proteolysis-targeting chimera, bavdegalutamide, seems to work best against two molecularly defined subtypes of advanced prostate cancer. According to phase I/II trial data presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium, the androgen receptor degrader most commonly shows antitumor activity among patients with T878X or H875Y mutations.
Topics & Concepts
Prostate cancerAndrogen receptorGenitourinary systemProstateCancer researchMedicineProteolysisOncologyInternal medicineCancerBiologyBioinformaticsBiochemistryEnzymeProtein Degradation and InhibitorsProstate Cancer Treatment and ResearchPeptidase Inhibition and Analysis